Abstract
Anti-CD38 monoclonal antibody treatment is known to interfere with the blood compatibility test. Dithiothreitol (DTT) pre-treatment to denature surface CD38 on the reagent erythrocytes is a robust method to mitigate this interference and has been validated internationally (Transfusion, 2016;56;2964-2972). However, the distribution of common alloreactive antibodies differed widely between Asian and Caucasian population. Furthermore, in addition to anti-K, it remains unknown whether DTT pretreatment will decrease the sensitivity in the detection of other allogeneic antibodies common in Asia like anti-Miltenberger (anti-Mia).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
